Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Classifica tra le azioni #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Prezzo delle azioni
$0.00047446
Capitalizzazione di mercato
$82.80
Variazione (1 giorno)
0.00%
Variazione (1 anno)
-98.16%
Paese
FR
Scambia Neovacs S.A. (ALNEV)

Categoria

Storico dividendi per Neovacs S.A. (ALNEV)
Neovacs S.A. (simbolo azionario: ALNEV) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Neovacs S.A. (ALNEV) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
52.00%
DK
0.00%
US
5.00%
US
29.00%
BE
0.00%
NL